SANEGENEBIO Trademark

Trademark Overview


On Tuesday, June 27, 2023, a trademark application was filed for SANEGENEBIO with the United States Patent and Trademark Office. The USPTO has given the SANEGENEBIO trademark a serial number of 98061872. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, December 24, 2024. This trademark is owned by Suzhou Sanegene Bio Co., Ltd.. The SANEGENEBIO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of various diseases, namely, rare ocular, renal, muscular, metabolic, immune system, cardiovascular, neurological and respiratory diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical preparations for pharmaceutical or medical purposes, namely, oligonucleotide compounds for use in the targeted delivery of Ribonucleic acid interference (RNAi) therapy; Pharmaceutical preparations for use in injection for treatment of rare ocular, renal, muscular, metabolic, immune system, cardiovascular, neurological and respiratory diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical preparations for pharmaceutical or medical purposes, namely, molecular nanoparticle complexes that act as a platform for the delivery of RNA based drugs to biological cells; Drug delivery agents consisting of oligonucleotide compounds that facilitate d...
sanegenebio

General Information


Serial Number98061872
Word MarkSANEGENEBIO
Filing DateTuesday, June 27, 2023
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, December 24, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 24, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of various diseases, namely, rare ocular, renal, muscular, metabolic, immune system, cardiovascular, neurological and respiratory diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical preparations for pharmaceutical or medical purposes, namely, oligonucleotide compounds for use in the targeted delivery of Ribonucleic acid interference (RNAi) therapy; Pharmaceutical preparations for use in injection for treatment of rare ocular, renal, muscular, metabolic, immune system, cardiovascular, neurological and respiratory diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical preparations for pharmaceutical or medical purposes, namely, molecular nanoparticle complexes that act as a platform for the delivery of RNA based drugs to biological cells; Drug delivery agents consisting of oligonucleotide compounds that facilitate delivery of a wide range of pharmaceuticals

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, July 30, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSuzhou Sanegene Bio Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressSuzhou, Jiangsu 215103
CN

Party NameSuzhou Sanegene Bio Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressSuzhou, Jiangsu 215103
CN

Trademark Events


Event DateEvent Description
Sunday, July 30, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 12, 2024ASSIGNED TO EXAMINER
Tuesday, March 12, 2024NON-FINAL ACTION WRITTEN
Tuesday, March 12, 2024NON-FINAL ACTION E-MAILED
Tuesday, March 12, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 8, 2024TEAS VOLUNTARY AMENDMENT RECEIVED
Wednesday, May 8, 2024TEAS VOLUNTARY AMENDMENT RECEIVED
Friday, June 7, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Friday, June 7, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, July 18, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 24, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 24, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 24, 2024ASSIGNED TO LIE
Tuesday, December 3, 2024EXAMINERS AMENDMENT E-MAILED
Tuesday, December 3, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 3, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, December 3, 2024EXAMINERS AMENDMENT -WRITTEN
Tuesday, December 3, 2024EXAMINER'S AMENDMENT ENTERED
Wednesday, December 18, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 24, 2024PUBLISHED FOR OPPOSITION
Tuesday, December 24, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED